Citadel Advisors’s Pacira BioSciences PCRX Stock Holding History

Citadel Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8,200	Closed	-$212K	–	13900
2025 Q4	$212K	Buy	+8,200	New	+$195K	﹤0.01%	10923
2025 Q3	–	Sell	-13,500	Closed	-$323K	–	13753
2025 Q2	$323K	Buy	13,500 +900	+7%	+$22.7K	﹤0.01%	9639
2025 Q1	$313K	Sell	12,600 -2,200	-15%	-$52.7K	﹤0.01%	9482
2024 Q4	$279K	Sell	14,800 -16,900	-53%	-$297K	﹤0.01%	9801
2024 Q3	$477K	Buy	31,700 +7,800	+33%	+$133K	﹤0.01%	8357
2024 Q2	$684K	Buy	23,900 +5,400	+29%	+$154K	﹤0.01%	7402
2024 Q1	$541K	Buy	18,500 +8,400	+83%	+$258K	﹤0.01%	8213
2023 Q4	$341K	Sell	10,100 -5,700	-36%	-$167K	﹤0.01%	8910
2023 Q3	$485K	Buy	15,800 +10,000	+172%	+$360K	﹤0.01%	8118
2023 Q2	$232K	Sell	5,800 -3,600	-38%	-$149K	﹤0.01%	9555
2023 Q1	$384K	Sell	9,400 -3,600	-28%	-$143K	﹤0.01%	8854
2022 Q4	$502K	Sell	13,000 -8,200	-39%	-$399K	﹤0.01%	8224
2022 Q3	$1.13M	Sell	21,200 -5,400	-20%	-$300K	﹤0.01%	6725
2022 Q2	$1.55M	Sell	26,600 -26,300	-50%	-$1.72M	﹤0.01%	6073
2022 Q1	$4.04M	Buy	52,900 +19,300	+57%	+$1.29M	﹤0.01%	4586
2021 Q4	$2.02M	Buy	33,600 +21,300	+173%	+$1.17M	﹤0.01%	6209
2021 Q3	$689K	Sell	12,300 -900	-7%	-$51.9K	﹤0.01%	9113
2021 Q2	$801K	Buy	13,200 +8,300	+169%	+$525K	﹤0.01%	8943
2021 Q1	$343K	Sell	4,900 -29,100	-86%	-$2.08M	﹤0.01%	10530
2020 Q4	$2.04M	Buy	34,000 +6,500	+24%	+$381K	﹤0.01%	5325
2020 Q3	$1.65M	Buy	27,500 +8,700	+46%	+$506K	﹤0.01%	5083
2020 Q2	$986K	Buy	18,800 +12,700	+208%	+$531K	﹤0.01%	5850
2020 Q1	$205K	Buy	+6,100	New	+$253K	﹤0.01%	7976
2019 Q4	–	Sell	-9,600	Closed	-$365K	–	9571
2019 Q3	$365K	Sell	9,600 -2,400	-20%	-$95.8K	﹤0.01%	7267
2019 Q2	$522K	Buy	12,000 +3,100	+35%	+$132K	﹤0.01%	6759
2019 Q1	$339K	Sell	8,900 -20,300	-70%	-$792K	﹤0.01%	7434
2018 Q4	$1.26M	Sell	29,200 -69,600	-70%	-$3.25M	﹤0.01%	4941
2018 Q3	$4.86M	Buy	98,800 +49,100	+99%	+$2.12M	﹤0.01%	3044
2018 Q2	$1.59M	Buy	49,700 +7,700	+18%	+$266K	﹤0.01%	4448
2018 Q1	$1.31M	Buy	42,000 +24,300	+137%	+$865K	﹤0.01%	4394
2017 Q4	$808K	Buy	17,700 +2,600	+17%	+$103K	﹤0.01%	4961
2017 Q3	$567K	Buy	15,100 +8,700	+136%	+$350K	﹤0.01%	5141
2017 Q2	$305K	Sell	6,400 -15,200	-70%	-$705K	﹤0.01%	5884
2017 Q1	$985K	Sell	21,600 -3,200	-13%	-$138K	﹤0.01%	4018
2016 Q4	$801K	Sell	24,800 -13,800	-36%	-$461K	﹤0.01%	4184
2016 Q3	$1.32M	Buy	38,600 +17,200	+80%	+$674K	﹤0.01%	3477
2016 Q2	$722K	Buy	21,400 +16,400	+328%	+$806K	﹤0.01%	3989
2016 Q1	$265K	Sell	5,000 -14,100	-74%	-$825K	﹤0.01%	5255
2015 Q4	$1.47M	Buy	19,100 +6,000	+46%	+$340K	﹤0.01%	3109
2015 Q3	$538K	Sell	13,100 -15,000	-53%	-$919K	﹤0.01%	4710
2015 Q2	$1.99M	Sell	28,100 -5,300	-16%	-$417K	﹤0.01%	3067
2015 Q1	$2.97M	Buy	33,400 +10,900	+48%	+$1.11M	﹤0.01%	2601
2014 Q4	$2M	Sell	22,500 -7,100	-24%	-$672K	﹤0.01%	2915
2014 Q3	$2.87M	Buy	29,600 +14,800	+100%	+$1.44M	﹤0.01%	2494
2014 Q2	$1.36M	Buy	+14,800	New	+$1.13M	﹤0.01%	3131

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors's PCRX Position: Q1 2026 in Review

Citadel Advisors reduced its Pacira BioSciences (PCRX) stake by 2.7% in Q1 2026, selling an estimated $500K and leaving 797,281 shares worth $18M. The position accounts for ﹤0.01% of the portfolio, ranked #2450.

Citadel Advisors first reported a position in PCRX in Q2 2013 and has held it in 48 quarters since. The position peaked at $44.8M in Q3 2016. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

Citadel Advisors held 797,281 shares of Pacira BioSciences worth $18M as of Q1 2026.
Citadel Advisors sold 22,487 Pacira BioSciences shares in Q1 2026, an estimated $500K.
Pacira BioSciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2450 holding.
Citadel Advisors first reported a position in Pacira BioSciences in Q2 2013 and has held it in 48 quarters since.
Citadel Advisors's Pacira BioSciences position peaked at $44.8M in Q3 2016.
241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.